Novo Nordisk A/S (NVO) experienced a significant intraday surge of 5.08%, marking a strong positive movement for the pharmaceutical giant.

The stock's ascent follows the company's announcement of a substantial DKK 3.8 billion share repurchase program as part of its 2026 buyback plan. Such corporate actions typically signal management's confidence in the company's value and future prospects, while reducing the number of shares outstanding can provide upward pressure on the stock price.

Concurrently, the White House launched the TrumpRx drug-pricing website, which includes Novo Nordisk's weight-loss medication Wegovy among its approximately 40 available drugs. This new direct-to-consumer channel, while offering discounted prices, expands the potential market reach for the company's flagship obesity treatment, potentially offsetting competitive concerns in the sector.